C635C019-A66D-42B7-911C-4D0742CAF95A
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 14.947437582128778
- age_years
- 56
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.662
- G2M_CHECKPOINT+0.602
- MYC_TARGETS_V1+0.602
- MYC_TARGETS_V2+0.563
- NOTCH_SIGNALING+0.440
- DNA_REPAIR+0.426
- MITOTIC_SPINDLE+0.371
- UNFOLDED_PROTEIN_RESPONSE+0.371
- PROTEIN_SECRETION+0.299
- TGF_BETA_SIGNALING+0.252
Top 10 suppressed
- MYOGENESIS-0.389
- KRAS_SIGNALING_DN-0.373
- XENOBIOTIC_METABOLISM-0.288
- IL6_JAK_STAT3_SIGNALING-0.265
- COAGULATION-0.262
- FATTY_ACID_METABOLISM-0.245
- INFLAMMATORY_RESPONSE-0.243
- CHOLESTEROL_HOMEOSTASIS-0.233
- ESTROGEN_RESPONSE_LATE-0.203
- ESTROGEN_RESPONSE_EARLY-0.190
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR934873 | — | — | 0.943 |
| 2 | SRR934990 | — | — | 0.939 |
| 3 | SRR934879 | — | — | 0.938 |
| 4 | SRR934744 | — | — | 0.936 |
| 5 | SRR934900 | — | — | 0.931 |
| 6 | 0D600773-1B42-4F04-BCEA-39F658DF63F1 | — | — | 0.924 |
| 7 | D902E43A-F384-432A-B690-D20BFCC78443 | — | — | 0.923 |
| 8 | 8BC036E8-0EA0-4346-A551-2A5F8975FEAB | — | — | 0.915 |
| 9 | SRR934893 | — | — | 0.909 |
| 10 | 9F4AEC07-5C91-4009-BA26-E4947CAA3391 | — | — | 0.909 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 22 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.662 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.602 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.602 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.563 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.440 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.426 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.371 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.371 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.299 | Remibrutinib | — uncovered |
| TGF_BETA_SIGNALING | 0.252 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.242 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.196 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.151 | Remibrutinib | — uncovered |
| GLYCOLYSIS | 0.118 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.102 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.099 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.065 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.047 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.035 | Remibrutinib | — uncovered |
| APOPTOSIS | 0.024 | Idelalisib | — uncovered |